Kalapurakal John A, Li Sierra M, Breslow Norman E, Beckwith J Bruce, Macklis Roger, Thomas Patrick R M, D'Angio Guilio J, Kim Tae, de Lorimier Alfred, Kelalis Panayotis, Shochat Steven, Ritchey Michael, Haase Gerald, Hrabovsky Ellen, Otherson H Biemann, Grundy Paul, Green Daniel M
Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):495-9. doi: 10.1016/s0360-3016(03)00598-4.
This study was undertaken to determine whether radiation therapy (RT) delay of >or=10 days had an adverse impact on abdominal tumor recurrence among children with favorable histology (FH) Wilms' tumor enrolled in National Wilms' Tumor Study (NWTS) 3 and 4.
A total of 1226 patients with Stage II-IV FH tumors who received flank or abdominal RT in NWTS-3 and NWTS-4 were included in this analysis. Recurrent disease in the operative bed was classified as flank recurrence. Abdominal recurrence included all infradiaphragmatic tumor recurrences, including flank recurrences. This analysis included all flank/abdominal tumor recurrences, regardless of whether they might have been the initial or subsequent site of relapse. Based on the NWTS-1 results, RT delay was analyzed in two categories: 0-9 days and >or=10 days.
The mean RT delay was 10.9 days; median delay was 9 days (range: 1-277 days). The RT delay was concentrated in a relatively narrow range of 8 to 12 days after nephrectomy in the majority of patients (59%). Univariate and multivariate analysis did not reveal RT delay of >or=10 days to significantly influence flank and abdominal tumor recurrence rates in NWTS-3 or NWTS-4. The 8-year flank tumor recurrence rates for 0-9 days and 10+ days RT delay were 1.9% and 1.2%, respectively (p value = 0.3). The 8-year abdominal tumor recurrence rates for 0-9 days and 10+ days RT delay were 4.8% and 5.3%, respectively (p value = 0.7).
RT delay of >or=10 days did not significantly influence flank or abdominal tumor recurrence rates among children with FH tumors treated on NWTS-3 and NWTS-4. However, we were unable to test for a meaningful difference, because of the concentration of RT delay close to 10 days.
本研究旨在确定放疗(RT)延迟≥10天是否会对参加国家肾母细胞瘤研究(NWTS)3和4的组织学良好(FH)肾母细胞瘤患儿的腹部肿瘤复发产生不利影响。
本分析纳入了1226例在NWTS-3和NWTS-4中接受侧腹或腹部放疗的II-IV期FH肿瘤患者。手术床的复发性疾病被分类为侧腹复发。腹部复发包括所有膈下肿瘤复发,包括侧腹复发。该分析包括所有侧腹/腹部肿瘤复发,无论它们可能是初始还是后续复发部位。基于NWTS-1的结果,放疗延迟分为两类:0-9天和≥10天。
放疗延迟的平均时间为10.9天;中位延迟为9天(范围:1-277天)。大多数患者(59%)的放疗延迟集中在肾切除术后相对较窄的8至12天范围内。单因素和多因素分析均未显示放疗延迟≥10天会对NWTS-3或NWTS-4中的侧腹和腹部肿瘤复发率产生显著影响。放疗延迟0-9天和10天及以上的8年侧腹肿瘤复发率分别为1.9%和1.2%(p值=0.3)。放疗延迟0-9天和10天及以上的8年腹部肿瘤复发率分别为4.8%和5.3%(p值=0.7)。
放疗延迟≥10天对在NWTS-3和NWTS-4接受治疗的FH肿瘤患儿的侧腹或腹部肿瘤复发率没有显著影响。然而,由于放疗延迟集中在接近10天的时间,我们无法检测到有意义的差异。